证券日报网讯 2月12日，创业慧康发布公告称，控股股东葛航于2026年2月9日至10日分笔解除质押合计 120814266股，占其原持股77.55%，对应质权人国元证券、巢湖新投、杭州更好均已办理登记，解押后 葛航仍质押2200万股，占其现持股37.13%。 （编辑 丛可心） ...

每经AI快讯，创业慧康2月12日晚间发布公告称，2月11日，公司收到股东葛航先生的《告知函》，获 悉葛航先生将其持有的本公司部分股票办理解除质押登记手续，解除质押共计约1.21亿股股票。截至本 公告日，葛航累计质押股数为2200万股，合计占其所持股份比例为37.13%。 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 （记者 王晓波） ...

创业慧康公告，股东葛航已解除质押股份1.21亿股，其中质押给国元证券6500.28万股、巢湖新投 2877.73万股、杭州更好2703.41万股，占其原持股77.55%、占公司总股本7.80%。解除后，葛航仍质押 2200万股，占其现持股37.13%、占公司总股本1.42%。 ...

证券代码：300451 证券简称：创业慧康 公告编号：2026-005 创业慧康科技股份有限公司 关于股东部分股份解除质押的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2026 年 2 月 11 日，创业慧康科技股份有限公司（以下简称"公司"）收到 股东葛航先生的《告知函》，获悉葛航先生将其持有的本公司部分股票办理解除 质押登记手续，具体包括：质押给国元证券股份有限公司（以下简称"国元证券"） （65,002,800 股）、巢湖新投房地产开发有限公司（以下简称"巢湖新投"） （28,777,331 股）、杭州更好智投管理咨询合伙企业（有限合伙）（以下简称"杭 州更好"）（27,034,135 股），共计 120,814,266 股股票，前述质权人均已办理 解除质押登记手续。现将具体内容公告如下： 注：上表中解除质押股数占其所持股份的比例为基于葛航先生协议转让过户 完成前的所持总股数（155,780,282 股）计算。 二、股东股份累计质押的情况 | | | | | | 累计 | | 合计 | 已质押股份 | | 未质押股份 | | | --- | --- ...

证券代码：300451 证券简称：创业慧康 公告编号：2026-004 创业慧康科技股份有限公司 关于筹划控制权变更事项进展暨协议转让股份完成过户 登记的公告 行事项（"向特定对象发行股票"）。此外，杭州更好拟向公司提名四名非独立 董事、两名独立董事人选（"董事会改选"）。无论公司是否完成向特定对象发 行股票事项，若杭州更好提名的上述董事全部当选且占公司董事会席位的半数以 上，将导致公司控制权变更，杭州更好成为公司的控股股东。 3、根据中国证券登记结算有限责任公司出具的《证券过户登记确认书》，本 次协议转让所涉及的股份已于 2026 年 2 月 11 日办理完成了过户登记手续。杭州 更好拥有公司股份 96,525,096 股，占公司总股本的 6.23%。 4、公司股东筹划控制权变更事项仍在进行中，董事会改选、向特定对象发行 股票等事项能否最终实施完成及实施结果尚存在不确定性。公司将持续关注后续 进展情况，并督促相关股东及时履行信息披露义务，敬请广大投资者理性投资， 注意投资风险。 一、协议转让概述 2025 年 11 月 12 日，杭州更好与葛航先生签署《股份转让协议》，受让葛 航先生持有的公司 96,525 ...

Core Viewpoint - The financial performance of Chuangyue Huikang (300451) shows significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and market position [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 862 million yuan, a year-on-year decrease of 26.26% [2]. - The net profit attributable to shareholders was -122 million yuan, reflecting a year-on-year decline of 331.69% [2]. - The net profit excluding non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the single-quarter main revenue was 285 million yuan, a decrease of 35.5% compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, down 264.2% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -47.40 million yuan, a decline of 288.66% year-on-year [2]. - The company's debt ratio stood at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan [2]. - The gross profit margin was reported at 49.87% [2]. Business Operations - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations [2]. - The company's offerings now include smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative solutions for system construction and operation services [2].

Core Viewpoint - The company emphasizes that the clawdbot has no direct impact on its existing business and is committed to advancing its "Huikang Cloud Strategic Planning" to enhance product innovation and system reliability [1] Group 1: Business Strategy - The company will focus on continuous product innovation and the deepening of core system applications, particularly HI-HIS, to improve system reliability and data security [1] - The company aims to optimize implementation processes and build a standardized delivery system to ensure efficient project execution [1] - Collaboration with ecosystem partners will be prioritized to integrate medical scene demands with cutting-edge technology, accelerating the transformation of R&D results [1] Group 2: Competitive Advantage - The company plans to strengthen its product technology barriers and core competitive advantages through enhanced development support and operational knowledge accumulation [1] - A standardized toolchain will be established to improve the professional capabilities of the delivery team, alongside a rapid deployment mechanism to address short-term market challenges [1] Group 3: Market Outlook - The company expresses confidence in the broad prospects of the medical information industry and the ongoing core demands of clients [1] - With enhanced product technology strength, improved project delivery efficiency, and innovative applications in the medical AI field, the company will continue to deepen its focus on the medical information sector [1] - The company aims to explore new models and paths for smart hospital construction in collaboration with various medical institutions, contributing to high-quality development in healthcare [1]

Group 1 - The stock price of Chuangye Huikang (300451) closed at 5.51 yuan on February 9, 2026, with an increase of 3.18% and a trading volume of 501,700 hands, resulting in a transaction amount of 275 million yuan [1] - On February 9, 2026, the net outflow of main funds was 1.826 million yuan, accounting for 0.66% of the total transaction amount, while retail investors had a net inflow of 5.7344 million yuan, accounting for 2.09% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net inflows from retail investors on several days despite overall negative net flows from main and speculative funds [1] Group 2 - Chuangye Huikang's total market value is 8.536 billion yuan, which is below the software development industry average of 13.721 billion yuan, ranking 77 out of 193 [2] - The company reported a net profit of -122 million yuan for the first three quarters of 2025, a significant decline of 331.69% year-on-year, with a gross margin of 49.87% [2] - The company's main business has shifted from product development and sales to a broader range of services, including smart healthcare, internet medical services, and health city solutions [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chuangyue Huikang (300451) as of February 5, 2026, showing a decline in stock price and significant net outflows from various investor categories [1][2]. Group 2 - Chuangyue Huikang reported a main revenue of 862 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 26.26% [2]. - The company experienced a net profit attributable to shareholders of -122 million yuan, a significant decline of 331.69% year-on-year [2]. - The net profit after deducting non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the company’s single-quarter main revenue was 285 million yuan, reflecting a 35.5% year-on-year decrease [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, a decline of 264.2% year-on-year [2]. - The company’s debt ratio stands at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan, while the gross profit margin is 49.87% [2]. Group 3 - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations, including areas such as smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative operational services [2].

Group 1 - Company Chuangyue Huikang Technology Co., Ltd. won a procurement project from China Construction Bank Liaoning Branch with a bid amount of 1.8 million yuan [1] - In 2024, the company's operating revenue was 1.423 billion yuan, with a revenue growth rate of -11.96% [2][3] - The net profit attributable to the parent company for 2024 was -174 million yuan, with a net profit growth rate of -572.96% [2][3] Group 2 - In the first half of 2025, the company's operating revenue was 577 million yuan, with a revenue growth rate of -20.65% [2][3] - The net profit attributable to the parent company for the first half of 2025 was -81 million yuan, with a net profit growth rate of -394.25% [2][3] - The company operates in the information technology industry, with main product types including industry-specific software, service (39.86%), software sales (39.55%), system integration and operation maintenance (10.74%), and hardware sales and others (9.85%) [2][3]